在患有膝关节骨关节炎的活跃患者群体中，膝关节镜检查后使用透明质酸钠凝胶G-F 20。

The use of hylan G-F 20 after knee arthroscopy in an active patient population with knee osteoarthritis.

作者信息

Zietz Patrick M, Selesnick Harlan

机构信息

West Michigan Orthopaedics, Grand Rapids, Michigan, USA.

出版信息

Arthroscopy. 2008 Apr;24(4):416-22. doi: 10.1016/j.arthro.2007.10.014.

DOI:10.1016/j.arthro.2007.10.014

PMID:18375273

Abstract

PURPOSE

The purpose of this study was to evaluate the efficacy of hylan G-F 20 when used to treat an active and athletic patient population with knee osteoarthritis who had undergone knee arthroscopy for mechanical symptoms.

METHODS

We performed a prospective evaluation of patients who underwent knee arthroscopy for mechanical symptoms. All patients had Outerbridge grade III or IV changes to their articular cartilage. If patients complained of residual pain or activity limitations postoperatively that was believed to be from osteoarthritis, they were treated with a series of hylan G-F 20 consisting of 3 weekly injections. International Knee Documentation Committee (IKDC) and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scores are reported for the time immediately before arthroscopy, at the time of the first hylan G-F 20 injection (baseline), at 3 months postoperatively, and at 6 months postoperatively. In addition, activity scores were calculated from a subset of the IKDC questionnaire before arthroscopy, at baseline, and at 3 months postoperatively.

RESULTS

Fifteen patients completed 6 months' follow-up. Baseline and 3- and 6-month IKDC and WOMAC scores were significantly improved compared with before arthroscopy. There was no significant difference in 3- and 6-month scores compared with baseline. The activity scores at baseline and at 3 months showed significant improvement compared with before arthroscopy. The activity scores also showed significant improvement at 3 months compared with baseline.

CONCLUSIONS

Hylan G-F 20 injections allow for improved activity levels at 3 months' follow-up. There was not a significant benefit of the injections when IKDC and WOMAC scores were evaluated. Hylan G-F 20 may be more beneficial for those patients who desire to increase their activity level rather than those who wish to decrease their pain.

LEVEL OF EVIDENCE

Level IV, therapeutic case series.

摘要

目的

本研究旨在评估透明质酸钠凝胶G-F 20用于治疗因机械性症状接受膝关节镜检查的活跃且爱运动的膝骨关节炎患者的疗效。

方法

我们对因机械性症状接受膝关节镜检查的患者进行了前瞻性评估。所有患者的关节软骨均有Outerbridge III级或IV级改变。如果患者术后仍有疼痛或活动受限，且认为是由骨关节炎引起的，则接受一系列透明质酸钠凝胶G-F 20治疗，每周注射1次，共3次。报告了国际膝关节文献委员会（IKDC）和西安大略和麦克马斯特大学骨关节炎指数（WOMAC）在关节镜检查前即刻、首次注射透明质酸钠凝胶G-F 20时（基线）、术后3个月和术后6个月的评分。此外，还根据IKDC问卷的一个子集计算了关节镜检查前、基线和术后3个月的活动评分。